Treating patients suffering from myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) with sodium dichloroacetate: An open-label, proof-of-principle pilot trial.

Why It Matters

This study addresses a persistent challenge in ME/CFS treatment by proposing a mechanistic hypothesis—mitochondrial dysfunction—and testing a targeted intervention. For patients with refractory ME/CFS, even preliminary evidence of a potential treatment warrants further investigation. The finding that approximately half the cohort responded well suggests heterogeneity in ME/CFS pathophysiology and the possibility that future diagnostic criteria could better identify responders to targeted therapies.

What This Study Does Not Prove

This study does not establish that sodium dichloroacetate is an effective ME/CFS treatment, as it lacks a control group, blinding, and placebo comparison—all essential for determining true treatment efficacy. The open-label design creates substantial risk for placebo effects and observer bias. The small sample size and failure to respond in half the cohort mean these findings cannot be generalized to the broader ME/CFS population, and the study cannot definitively prove mitochondrial hypo-metabolism causes ME/CFS.

Tags